Work

Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− metastatic breast cancer?

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.11.003

Authors: A. Giordano, N.U. Lin, S.M. Tolaney, E.L. Mayer

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, Daiichi-Sankyo

OpenAlex ID: W4388598899

FWCI: 0.921

Cites: 43

Cited by: 5

Related to: 10